Por favor, use este identificador para citar o enlazar este ítem: https://hdl.handle.net/11000/31402
Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.contributor.authorEscorial, Mónica-
dc.contributor.authorMuriel, Javier-
dc.contributor.authorCésar, Margarit-
dc.contributor.authorLaura, Agulló-
dc.contributor.authorDomingo, Morales-
dc.contributor.authorPeiró, Ana-
dc.contributor.otherDepartamentos de la UMH::Medicina Clínicaes_ES
dc.date.accessioned2024-02-09T16:33:32Z-
dc.date.available2024-02-09T16:33:32Z-
dc.date.created2022-
dc.identifier.citationBiomedicines . 2022 Sep 16;10(9):2302es_ES
dc.identifier.issn2227-9059-
dc.identifier.urihttps://hdl.handle.net/11000/31402-
dc.description.abstractBackground: It is essential to focus attention on sex-specific factors which are clinically relevant in pain management, especially with regards to opioid use disorder (OUD) risk. The aim of this study was to explore potential sex-differences in chronic non-cancer pain (CNCP) outpatients. (2) Methods: An observational cross-sectional study was conducted under CNCP outpatients with long-term prescribed opioids (n = 806), wherein 137 patients had an OUD diagnosis (cases, 64% females) and 669 did not (controls, 66% females). Socio-demographic, clinical, and pharmacological outcomes were analyzed. (3) Results: Female controls presented an older age and less intensive pain therapy but higher psychotropic prescriptions and emergency department visits compared to male controls. Meanwhile, cases demonstrated a younger age, higher work disability, double morphine equivalent daily dose, and benzodiazepine use compared with controls. Here, female cases showed an 8% greater substance use disorder (OR 2.04 [1.11-3.76]) and 24% lower tramadol use, while male cases presented a 22% higher fentanyl use (OR 2.97 [1.52-5.81]) and reported the highest number of adverse drug reactions (24%, OR 2.40 [1.12-5.16]) compared with controls. (4) Conclusions: An OUD individual risk profile was evidenced with sex-differences to take into consideration to design equal prevention programs.es_ES
dc.formatapplication/pdfes_ES
dc.format.extent11es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectopioid use disorderes_ES
dc.subjectsex-differenceses_ES
dc.subjectchronic non-cancer pain;es_ES
dc.subjectgender disparitieses_ES
dc.subjectpain managementes_ES
dc.subjectprevention programses_ES
dc.titleSex-Differences in Pain and Opioid Use Disorder Management: A Cross-Sectional Real-World Studyes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.contributor.instituteInstitutos de la UMH::Instituto de Bioingenieríaes_ES
dc.relation.publisherversionhttps://doi.org/10.3390/biomedicines10092302es_ES
Aparece en las colecciones:
Artículos Farmacología, Pediatría y Química Orgánica


Vista previa

Ver/Abrir:
 Sex-Differences in Pain and Opioid Use Disorder Management.pdf

829,64 kB
Adobe PDF
Compartir:


Creative Commons La licencia se describe como: Atribución-NonComercial-NoDerivada 4.0 Internacional.